Regeneron Pharmaceuticals, Inc. (REGN)

Health Care · Biotechnology · US stock · S&P 500 component

$819.09 ▲ +13.42 (1.67%)

At close 22 Oct 2026 · USD · Volume 852,286

Compare with AMGN

Interactive chart Research report Forecast ranges Pro workspace SEC filings Historical data

Fair valueFair

$794 −3.1% to fair value

$397fair band $676–$963$1,191

Day's range

$800.00 – $825.52

52-week range

$572.75 – $859.34

About Regeneron Pharmaceuticals, Inc.

Regeneron is a biotechnology company that discovers, develops and commercialises medicines for serious diseases. Its marketed products include Eylea for eye conditions and Libtayo for certain cancers, and it shares in the Dupixent antibody medicine developed with Sanofi, which treats several inflammatory conditions. Much of its research relies on its own antibody technology platforms. It supplies hospitals, clinics and specialty providers through distributors and works with partner companies on development.

Revenue comes from product sales and from collaboration income, including its share of Dupixent profits. Sales were $15.5 billion over the last twelve months, up 5.6% a year over the last three years, with an operating margin of 24.7%. The business earns a profit of 13% on the capital invested in it and has net debt of -1.4 times EBITDA, meaning it holds more cash than debt. A dividend is paid, with a yield of 0.5%. On the site's X-Ray Score it receives 47 out of 100.

Price chart

Interactive chart Historical data & CSV

52-wk range $572.75 – $859.34Volume 852,286Daily, split-adjusted

Vitals

Market cap$86.8B

52-week range$572.75 – $859.34

Volume (last day)852,286

P/E (TTM)20.3

EBIT / EV yield4.8%

Free-cash-flow yield4.3%

Dividend yield0.5%

Revenue (TTM)$15.5B

Net income (TTM)$4.3B

Operating margin24.7%

Return on capital12.5%

Debt incl. leases$2.0B

Cash & securities$8.0B

Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.

Fair value estimate

$794middle half of models $776 – $843

Fair −3.1% to fair value

Average of the 13 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is Medium, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.

Price $819

Undervalued < $676Fair $676 – $963Overvalued > $963

P/E multiple

$810

P/B multiple

$1,102

P/S multiple

$851

EV/EBITDA multiple

$809

EV/EBIT multiple

$776

EV/revenue multiple

$874

10-year DCF, EBITDA exit

$799

5-year DCF, EBITDA exit

$831

10-year DCF, revenue exit

$796

5-year DCF, revenue exit

$843

10-year DCF, growth exit

$541

5-year DCF, growth exit

$517

Dividend discount, stable · not used

$128

Dividend discount, multi-stage · not used

$250

Earnings power value

$775

Growth the price implies

17.3%/yr

A model estimate, not a price target or recommendation. Inputs: risk-free 5.13%, equity risk premium 4.30% (Damodaran). How it works.

What this means

Average business, fairly priced

The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.

Before you invest · decision checklist

I understand how this company makes money Business quality is average or better ✓ 54 The price is not above fair value $794 fair value Debt looks manageable -1.4× EBITDA Revenue has been growing 5.6% a year Profits are backed by cash There are no red flags none raised I know what share of my savings this would be

Ticked boxes are filled in from our data; the rest are yours to answer.

The five-lens scan

Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.

Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data

Valuation Fair

52/100

Priced about in line with its sector.

See the numbers →

EBIT / EV yield4.8%

Free-cash-flow yield4.3%

Fair value vs price1.0×

Growth Weak

34/100

Growing slower than most of its sector.

See the numbers →

Revenue growth (3y)5.6%

EPS growth (3y)2.8%

Growth consistency80%

Profitability Weak

37/100

Earns lower returns on its capital than most peers.

See the numbers →

Return on invested capital12.5%

Operating margin24.7%

Financial health Strong

72/100

Balance sheet looks strong: debt is well covered.

See the numbers →

Piotroski F-Score5 / 9

Net debt / EBITDA-1.4×

Interest coverNo interest cost

Dividends Weak

40/100

Dividend is modest or less certain than peers.

See the numbers →

Dividend yield0.5%

Dividends vs free cash flow10%

Quarterly results: last 6 quarters

-3.7%

Mar '25

+3.6%

Jun '25

+0.9%

Sep '25

+2.5%

Dec '25

+19.0%

Mar '26

+16.7%

Jun '26

Revenue against the same quarter a year earlier. Latest quarter revenue $4.3B, diluted EPS $12.23.

Compare with peers

INCY Incyte Corp80 VRTX Vertex Pharmaceuticals...50 AMGN Amgen Inc48 BIIB Biogen Inc.44

Other Biotechnology companies by X-Ray Score.

SWOT analysis: Regeneron Pharmaceuticals, Inc.

Strengthsinside the company

Cash exceeds debt (net debt is negative), which gives room to invest or ride out a downturn.
Operating profit covers interest 69x, so debt costs are a small drag.

Weaknessesinside the company

No clear weakness in the figures we track.

Opportunitiesvaluation and setting

Trades at 20.1x earnings, 28% below the 27.8x median of industry peers.
Price momentum is strong on the weekly and monthly signals (trends can reverse).

Threatsvaluation and setting

No specific threat is flagged by our checks; general market and interest-rate risk still applies.

Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.

Compare REGN with peers and sector

Medians of 7 Biotechnology peers and of 59 Health Care stocks in our universe. Largest peers (X-Ray Score): ABBV 41, AMGN 48, GILD 37, VRTX 50, MRNA 12, BIIB 44.

Metric	REGN	Peers	Sector
X-Ray Score (out of 100)	47	44	49
Valuation	52	26	55
Growth	34	45	48
Profitability	37	55	51
Financial health	71	38	48
Dividends	39	52	52

Sector leaders: highest X-Ray Score in Health Care

REGN ranks #35 of 60 in Health Care and #4 of 8 in Biotechnology by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.

Company	X-Ray Score
#1 INCY Incyte Corp	80
#2 DXCM Dexcom Inc	78
#3 PODD Insulet Corp	72
#4 RMD Resmed Inc	70
#5 ZTS Zoetis Inc.	69
…
#35 REGN Regeneron Pharmaceuticals,... (this stock)	47

Metric	REGN	Peers	Sector
P/E ratio	20.1x	27.8x	28.4x
PEG ratio	7.25	5.04	2.29
Price / book	2.7x	9.3x	4.0x
Price / sales	5.6x	6.4x	3.6x
EV / EBITDA	18.5x	20.3x	17.5x
Price / free cash flow	23.1x	23.9x	22.3x
Dividend yield	0.5%	2.2%	1.1%
Gap to our fair value	−3.1%	−15.3%	−1.0%

Metric	REGN	Peers	Sector
Price change, 1 month	+1.9%	+8.2%	+7.6%
Price change, 3 months	+25.9%	+21.3%	+13.3%
Price change, 6 months	+10.0%	+31.0%	+22.3%
Price change, 1 year	+40.8%	+32.8%	+20.7%

Metric	REGN	Peers	Sector
Market value	$86.8B	$136.6B	$49.2B
Revenue (last 12 months)	$15.5B	$12.6B	$14.3B
EBITDA (last 12 months)	$4.4B	$2.7B	$2.7B
Net income (last 12 months)	$4.3B	$1.4B	$1.4B
Free cash flow (last 12 months)	$3.8B	$7.0B	$2.1B

Metric	REGN	Peers	Sector
Revenue growth, last year	+1.0%	+8.6%	+7.2%
Revenue growth, 3 years a year	+5.6%	+2.6%	+5.5%
EPS growth, 3 years a year	+2.8%	+5.8%	+5.5%
Free cash flow growth, 3 years a year	−2.7%	−2.7%	+4.5%
Dividend growth	–	+5.1%	+4.2%

Metric	REGN	Peers	Sector
Gross margin	–	75.5%	65.0%
EBITDA margin	28.1%	27.2%	20.5%
Operating margin	24.7%	26.2%	15.8%
Net margin	27.9%	13.8%	10.0%
Return on invested capital	12.5%	17.7%	11.8%
Return on equity	13.7%	14.6%	13.6%

Metric	REGN	Peers	Sector
Net debt / EBITDA	-1.4x	3.1x	2.0x
Interest cover	69.4x	6.3x	9.3x
Current ratio	3.3x	2.3x	1.5x
Piotroski F-score (0 to 9)	5	7	6

Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.

Factor ratings for REGN

Each factor is rated by where REGN stands among the 60 Health Care stocks in our universe.

Rating against the sector

Goodthe top third of these stocks

Averagethe middle third of these stocks

Badthe bottom third of these stocks

"Beats" is the share of those stocks it is ahead of.

Against its own history

The last columns set today's figure against the company's own median of its last five financial years:

▲ Betterbetter than its usual level

▼ Worseworse than its usual level

≈ In linewithin its usual range

For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.

In total: 8 Good · 8 Average · 5 Bad of 21 Growth: 0 · 2 · 1 Profitability: 2 · 2 · 0 Financial strength: 3 · 0 · 1 Valuation: 2 · 3 · 0 Cash flow: 1 · 1 · 2 Efficiency: 0 · 0 · 1

Factor	REGN	Rating	Sector median	Own 5-year median	Against own history
Growth
Revenue growth, 3 years a year	+5.6%	Average beats 54%	+5.5%	–	–
Revenue growth, last year	+1.0%	Bad beats 16%	+7.1%	+7.8%	▼ Worse
EPS growth, 3 years a year	+2.8%	Average beats 42%	+5.0%	–	–
Profitability
Operating margin	24.7%	Good beats 76%	16.4%	30.9%	▼ Worse
Net margin	27.9%	Good beats 92%	11.1%	31.4%	▼ Worse
Return on invested capital	12.5%	Average beats 51%	12.2%	–	–
Return on equity	13.7%	Average beats 50%	13.7%	15.2%	≈ In line
Financial strength
Net debt / EBITDA	-1.4x	Good beats 93%	2.0x	-1.6x	≈ In line
Interest cover	69.4x	Good beats 94%	9.4x	50.0x	▲ Better
Current ratio	3.34	Good beats 91%	1.52	4.73	▼ Worse
Piotroski F-score	5 / 9	Bad beats 25%	6 / 9	–	–
Valuation
P/E ratio	20.1x	Good beats 78%	28.2x	18.6x	≈ In line
Price / book	2.7x	Good beats 68%	3.7x	3.6x	▲ Better
Price / sales	5.6x	Average beats 36%	3.7x	5.8x	≈ In line
EV / EBITDA	18.5x	Average beats 41%	17.6x	16.8x	▼ Worse
Free cash flow yield	4.3%	Average beats 47%	4.4%	4.9%	≈ In line
Cash flow
Free cash flow margin	24.2%	Good beats 76%	16.3%	29.5%	▼ Worse
Cash from operations / net income	1.08	Bad beats 11%	1.61	1.11	≈ In line
Free cash flow growth, 3 years a year	−2.7%	Average beats 34%	+4.3%	–	–
Accruals (lower is better)	−0.8%	Bad beats 4%	−3.9%	–	–
Efficiency
Days sales outstanding	154 days	Bad beats 3%	62 days	158 days	≈ In line

These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings). A dash in the history columns means fewer than three usable years.

Fundamentals checklist

● 5 Good · ● 7 Average · ● 3 Bad

Cash quality

Earnings backed by cashBad

Free-cash-flow yieldAverage

Risk models

Altman Z''Good

Piotroski F-ScoreBad

Growth

EPS growth (3y)Average

Free-cash-flow growth (3y)Average

Revenue growth (3y)Average

Growth consistencyBad

Balance sheet

Current ratioGood

Net debt / EBITDAGood

Interest coverGood

Valuation

Fair value vs priceAverage

EBIT / EV yieldAverage

Profitability

Return on invested capitalAverage

Operating marginGood

Each check is graded against the company's sector, not a fixed number. Checklist score 55/100.

Financials

	FY21	FY22	FY23	FY24	FY25
Revenue	$16.1B	$12.2B	$13.1B	$14.2B	$14.3B
Operating income	$8.9B	$4.7B	$4.0B	$4.0B	$3.6B
Net income	$8.1B	$4.3B	$4.0B	$4.4B	$4.5B
Operating cash flow	$7.1B	$5.0B	$4.6B	$4.4B	$5.0B
Operating margin	55.7%	38.9%	30.9%	28.1%	24.9%
Free cash flow	$6.5B	$4.4B	$3.9B	$3.7B	$4.1B
Diluted EPS	$71.97	$38.22	$34.77	$38.34	$41.48

Fiscal years, from SEC filings.

Technical summary

Daily

Strongly bullish

12 bullish · 1 neutral · 3 bearish

Weekly

Strongly bullish

11 bullish · 1 neutral · 0 bearish

Monthly

Strongly bullish

7 bullish · 1 neutral · 0 bearish

Moving averages (daily)

SMA 10	784.2	Bullish
EMA 10	789.3	Bullish
SMA 20	765.4	Bullish
EMA 20	780.3	Bullish
SMA 50	791.3	Bullish
EMA 50	771.4	Bullish
SMA 100	729.3	Bullish
EMA 100	752.4	Bullish
SMA 200	734.8	Bullish
EMA 200	730.7	Bullish

Oscillators (daily)

RSI (14)	63.52	Neutral
MACD (12, 26)	7.20	Bullish
Momentum (12)	10.88	Bullish
Stochastic %K (14)	93.79	Bearish
Williams %R (14)	-6.21	Bearish
CCI (20)	134.9	Bearish

Pivot points (classic, last session)

778.7

789.4

804.2

Pivot

814.9

829.7

840.4

855.3

Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Dividends

Paid, last 12 months

3.70 USD

Yield on today's price

0.45%

Frequency

Quarterly

Next ex-dividend date

Not announced

Ex-dividend date	Amount per share
18 Aug 2026	0.9400
20 May 2026	0.9400
20 Feb 2026	0.9400
20 Nov 2025	0.8800
18 Aug 2025	0.8800
20 May 2025	0.8800
20 Feb 2025	0.8800

Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.

ETFs that hold REGN

ETF	Share of the fund
IBB iShares Biotechnology	4.91%
FBT First Trust NYSE Arca Biotechnology In...	2.25%
PWV Invesco Dynamic Large Cap Value	1.59%
COWZ Pacer US Cash Cows 100	1.36%
IYH iShares U.S. Healthcare	1.27%
QQQE Direxion NASDAQ-100 Equal Weighted Ind...	1.26%
FHLC Fidelity MSCI Health Care Index	1.15%
XLV Health Care Select Sector SPDR	1.08%

The eight funds with the largest weight in REGN among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.